M. Cazzola (Rome, Italy), L. Donnelly (London, United Kingdom)
Effect of aclidinium bromide on exacerbations in patients with moderate-to-severe COPD: Pooled analysis of phase III studies
J. A. Wedzicha, G. Donaldson, F. Chuecos, E. Garcia Gil (London, United Kingdom; Barcelona, Spain)
|  |
1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthma
A. Boner, E. Hamelmann, J. Bernstein, P. Moroni-Zentgraf, M. Engel, M. Avis, A. Unseld, M. Vandewalker (Verona, Italy; Bochum, Ingelheim am Rhein, Biberach an der Riss, Germany; Cincinnati, Columbia, United States Of America; Alkmaar, Netherlands)
|   |
The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study
H. Magnussen, P. Chanez, R. Dahl, M. Decramer, B. Disse, H. Finnigan, A. Kirsten, R. Rodriguez-Roisin, K. Tetzlaff, L. Towse, H. Watz, E. Wouters, P. Calverley (Grosshansdorf, Ingelheim, Tübingen, Germany; Marseille, France; Odense, Denmark; Leuven, Belgium; Berkshire, Liverpool, United Kingdom; Barcelona, Spain; Maastricht, Netherlands)
| |
Pearl's PT010 triple combination provides comparable budesonide exposure to symbicort and comparable glycopyrronium and formoterol exposure to PT003
C. Reisner, C. Fernandez, P. Darken, P. DePetrillo, E. St. Rose, T. Fischer, S. Strom, M. Kong, K. Wong, S. Siddiqui, G. Tardie, C. Orevillo (Morristown, Baltimore, Raleigh, United States Of America; Markham, Canada)
| |
Repeated-dose pharmacokinetics of once-daily TD-4208, a long-acting muscarinic receptor antagonist (LAMA), in subjects with COPD
D. Bourdet, C. Barnes, W. Yates, E. Moran, A. Nicholls, B. Haumann (South San Francisco, United States Of America)
| |
QVA149 showed significant improvements in lung function and health status and was well tolerated versus glycopyrronium and tiotropium in patients with severe COPD: The SPARK study
J. A. Wedzicha, A. D'Urzo, K. Mezzi, H. Chen, D. Banerji, R. Fogel (London, United Kingdom; Toronto, Canada; Basel, Switzerland; East Hanover, United States Of America)
| |
Once-daily tiotropium respimat add-on to ICS±LABA improves control across asthma severities
J. M. FitzGerald, H. Kerstjens, P. Paggiaro, K. Ohta, M. Ichinose, P. Moroni-Zentgraf, M. Engel, H. Schmidt, E. Bateman (Vancouver, Canada; Groningen, Netherlands; Pisa, Italy; Tokyo, Sendai, Japan; Ingelheim am Rhein, Biberach an der Riss, Germany; Cape Town, South Africa)
| |
Once-daily tiotropium and olodaterol fixed-dose combination via the respimat improves outcomes vs mono-components in COPD in two 1-year studies
R. Buhl, E. Derom, G. Ferguson, F. Maltais, E. Pizzichini, J. Reid, H. Watz, L. Groenke, A. Hamilton, K. Tetzlaff, L. Korducki, H. Huisman, S. Waitere-Wijker, E. Bateman (Mainz, Grosshansdorf, Ingelheim, Tübingen, Germany; Ghent, Belgium; Livonia, Ridgefield, United States Of America; Québec, Burlington, Canada; Santa Catarina, Brazil; Dunedin, New Zealand; Alkmaar, Netherlands; Cape Town, South Africa)
| |